Novel biomarkers for drug-induced liver injury

Humphries, Christopher; Dear, James W.

doi:10.1080/15563650.2023.2259089

Cited by 5 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Food and Drug Administration (FDA) approved ALT use in 2009 for evaluating drug-induced liver toxicity (DILI), and it remains integral to the FDA-recommended approach for assessing DILI severity [40]. However, numerous novel liver-related biomarkers have emerged, such as cytokeratin-18, macrophage colonystimulating factor receptor 1, and osteopontin [41][42][43]. The main disadvantage of these biomarkers, in contrast to miR-122, is that they are not liver-specific, and their fluctuations during ASCT may reflect the total impact of chemotherapy responses elicited on all tissues.…”

Section: Discussionmentioning

confidence: 99%

Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

Mikulski,

Kościelny,

Dróżdż

et al. 2024

IJMS

View full text Add to dashboard Cite

Hepatic complications are an acknowledged cause of mortality and morbidity among patients undergoing hematopoietic stem cell transplantation. In this study, we aimed to evaluate the potential role in the prediction of liver injury of five selected microRNAs (miRNAs)—miR-122-5p, miR-122-3p, miR-15b-5p, miR-99b-5p, and miR-125a-5p—in the setting of autologous hematopoietic stem cell transplantation (ASCT). A total of 66 patients were included in the study: 50 patients (75.8%) with multiple myeloma (MM) and 16 (24.2%) with lymphoma. Blood samples were collected after the administration of the conditioning regimen, on the day of transplant (day 0). The expression levels of selected miRNAs were quantified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) using the miRCURY LNA miRNA Custom PCR Panels (QIAGEN). In a multivariate logistic regression analysis adjusted for age, sex, and the administered conditioning regimen, two miRNAs, hsa-miR-122-5p (odds ratio, OR 2.10, 95% confidence interval, CI: 1.29–3.42, p = 0.0029) and hsa-miR-125a-5p (OR 0.27, 95% CI: 0.11–0.71, p = 0.0079), were independent for hepatic toxicity occurrence during the 14 days after transplant. Our model in 10-fold cross-validation preserved its diagnostic potential with a receiver operating characteristics area under the curve (ROC AUC) of 0.75, 95% CI: 0.63–0.88 and at optimal cut-off reached 72.0% sensitivity and 74.4% specificity. An elevated serum level of miR-122-5p and decreased level of miR-125a-5p on day 0 are independent risk factors for hepatotoxicity in ASCT recipients, showing promise in accurately predicting post-ASCT complications. Identifying patients susceptible to complications has the potential to reduce procedure costs and optimize the selection of inpatient or outpatient procedures.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

Mikulski,

Kościelny,

Dróżdż

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

The emerging role of alternatively activated macrophages to treat acute liver injury

Humphries,

Addison,

Dear

et al. 2024

Arch Toxicol

View full text Add to dashboard Cite

Acute liver injury (ALI) has a clear requirement for novel therapies. One emerging option is the use of alternatively activated macrophages (AAMs); a distinct subtype of macrophage with a role in liver injury control and repair. In this comprehensive review, we provide an overview of the current limited options for ALI, and the potential advantages offered by AAMs. We describe the evidence supporting their use from in vitro studies, pre-clinical animal studies, and human clinical trials. We suggest why the first evidence for the clinical use of AAMs is likely to be found in acetaminophen toxicity, and discuss the specific evidence for AAM use in this population, as well as potential applications for AAMs in other patient populations. The key domains by which the performance of AAMs for the treatment of ALI will be assessed are identified, and remaining challenges to the successful delivery of AAMs to clinic are explored.

show abstract

Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973–2023 with particular focus on contributions published from Edinburgh and Denver

Bateman,

Dart,

Dear

et al. 2023

Clinical Toxicology

View full text Add to dashboard Cite

Novel biomarkers for drug-induced liver injury

Cited by 5 publications

References 27 publications

Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

The emerging role of alternatively activated macrophages to treat acute liver injury

Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973–2023 with particular focus on contributions published from Edinburgh and Denver

Contact Info

Product

Resources

About